Clinical Trial: Alirocumab for Stabilisation of Symptomatic Vulnerable Carotid Plaque

U.S., May 15 -- ClinicalTrials.gov registry received information related to the study (NCT07586540) titled 'Alirocumab for Stabilisation of Symptomatic Vulnerable Carotid Plaque' on May 08.

Brief Summary: CAROTID-STABILISE is a phase III, multicentre, randomised, double-blind, placebo-controlled trial evaluating whether alirocumab 150 mg subcutaneously every 2 weeks, added to high-intensity statin therapy, produces greater reduction in intraplaque haemorrhage (IPH) volume at 26 weeks compared with placebo in patients with recently symptomatic carotid stenosis of 50-69% harbouring IPH or lipid-rich necrotic core (LRNC) on high-resolution vessel-wall MRI. The study will enroll 280 participants across multiple centres with a 52-week extension...